molecular targeted approaches for advanced braf v600, n-ras, c-kit, and gnaq melanomas

Clicks: 6
ID: 186279
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #190 of 193 articles by views in international journal of psychology : journal international de psychologie

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 193 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to have a good molecular stratification of those patients who may benefit from this therapeutic option. Practically, BRAF mutation status (V600E) is commonly screened although other non-V600E mutations (i.e., K-R-M-D) could be found in some patients who respond to therapy equally to the patients harboring V600E mutations. Furthermore, other mutations, namely, N-RAS, KIT, and GNAQ, should be sequenced according to distinct melanoma specific subtypes and clinical aspects. In our report, a practical flow chart is described along with our experience in this field.
Reference Key
giovanni2014diseasemolecular Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Ponti Giovanni;Pellacani Giovanni;Tomasi Aldo;Loschi Pietro;Luppi Gabriele;Gelsomino Fabio;Longo Caterina
Journal international journal of psychology : journal international de psychologie
Year 2014
DOI
10.1155/2014/671283
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.